CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) Plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

openalex(2023)

引用 0|浏览0
暂无评分
摘要
Consolidated supplementary appendix: tables, figures, text plus legends
更多
查看译文
关键词
Combination Therapies
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要